{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T09:10:06Z","timestamp":1754039406949,"version":"3.41.2"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We reviewed prominent national and international guidelines to compare recommendations for laboratory monitoring for persons on antiretroviral therapy. The United States Department of Health and Human Services guidelines recommend more frequent CD4 count, viral load, hematologic, renal, and liver tests than other guidelines. To evaluate the evidence base for these recommendations, we reviewed phase 3 trials of currently recommended antiretroviral regimens and large cohort studies. Cohort studies have consistently shown that persons with sustained viral suppression have stable or increasing CD cell counts, so it is not clear how continued CD4 count monitoring contributes to clinical care. Long-term safety data from trials and observational cohorts show little evidence to support hematologic, hepatic, or renal monitoring (apart from persons on tenofovir disoproxil fumarate). It is time to use the available data from clinical trials and cohort studies to develop evidence-based recommendations for laboratory monitoring tests for persons with viral suppression.<\/jats:p>","DOI":"10.1093\/cid\/ciae542","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T20:41:23Z","timestamp":1733863283000},"page":"113-118","source":"Crossref","is-referenced-by-count":0,"title":["Toward Evidence-based Recommendations for Laboratory Monitoring for Adolescents and Adults on Antiretroviral Therapy"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-1825","authenticated-orcid":false,"given":"William J","family":"Burman","sequence":"first","affiliation":[{"name":"Public Health Institute at Denver Health and the Department of Medicine at the University of Colorado School of Medicine, Denver, Colorado ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2380-6093","authenticated-orcid":false,"given":"Kellie L","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Public Health Institute at Denver Health and the Department of Medicine at the University of Colorado School of Medicine, Denver, Colorado ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"author":"Department of Health and Human Services","key":"2025080104321667600_ciae542-B1"},{"author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","key":"2025080104321667600_ciae542-B2"},{"author":"British HIV Association","key":"2025080104321667600_ciae542-B3"},{"author":"European AIDS Clinical Society","key":"2025080104321667600_ciae542-B4"},{"author":"World Health Organization","first-page":"1","key":"2025080104321667600_ciae542-B5"},{"author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","key":"2025080104321667600_ciae542-B6"},{"key":"2025080104321667600_ciae542-B7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2025080104321667600_ciae542-B8","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/cid\/cit004","article-title":"Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts &gt;=300 cells\/muL and HIV-1 suppression?","volume":"56","author":"Gale","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025080104321667600_ciae542-B9","doi-asserted-by":"crossref","first-page":"20061","DOI":"10.7448\/IAS.18.1.20061","article-title":"CD4 changes among virologically suppressed patients on antiretroviral therapy: a systematic review and meta-analysis","volume":"18","author":"Ford","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"2025080104321667600_ciae542-B10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12879-017-2199-x","article-title":"Is it still worthwhile to perform quarterly CD4+ T lymphocyte cell counts on HIV-1 infected stable patients?","volume":"17","author":"Di Biagio","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2025080104321667600_ciae542-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hiv.12951","article-title":"Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana","volume":"22","author":"Leeme","year":"2021","journal-title":"HIV Med"},{"key":"2025080104321667600_ciae542-B12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/cid\/ciw146","article-title":"Effects of CD4 cell counts and viral load testing on mortality rates in patients with HIV infection receiving antiretroviral treatment: an observational cohort study in rural southwest China","volume":"63","author":"Shen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025080104321667600_ciae542-B13","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2025080104321667600_ciae542-B14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2025080104321667600_ciae542-B15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2025080104321667600_ciae542-B16","doi-asserted-by":"crossref","first-page":"e3572","DOI":"10.1093\/cid\/ciaa1391","article-title":"Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025080104321667600_ciae542-B17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025080104321667600_ciae542-B18","doi-asserted-by":"crossref","first-page":"ofae007","DOI":"10.1093\/ofid\/ofae007","article-title":"Final 192-week efficacy and safety results of the ADVANCE trial, comparing 3 first-line antiretroviral regimens","volume":"11","author":"Sokhela","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025080104321667600_ciae542-B19","doi-asserted-by":"crossref","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025080104321667600_ciae542-B20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/25787489.2021.2003132","article-title":"Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study","volume":"22","author":"Pelchen-Matthews","year":"2021","journal-title":"HIV Res Clin Pract"},{"key":"2025080104321667600_ciae542-B21","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1093\/cid\/ciac708","article-title":"Liver inflammation is common and linked to metabolic derangements in persons with treated human immunodeficiency virus (HIV)","volume":"76","author":"Chew","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025080104321667600_ciae542-B22","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1093\/cid\/ciu617","article-title":"Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"59","author":"Lucas","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025080104321667600_ciae542-B23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2025080104321667600_ciae542-B24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/135965350801300215","article-title":"Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial","volume":"13","author":"Phillips","year":"2008","journal-title":"Antivir Ther"},{"issue":"Suppl 1","key":"2025080104321667600_ciae542-B25","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc19-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2025080104321667600_ciae542-B26","doi-asserted-by":"crossref","first-page":"e14605","DOI":"10.1111\/dme.14605","article-title":"HIV infection and anaemia do not affect HbA(1c) for the detection of diabetes in black South Africans: evidence from the Durban Diabetes Study","volume":"38","author":"Hird","year":"2021","journal-title":"Diabet Med"},{"key":"2025080104321667600_ciae542-B27","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2337\/dc24-0225","article-title":"What is the influence of HIV serostatus on HbA1c? A prospective analysis using continuous glucose monitoring","volume":"47","author":"Daultrey","year":"2024","journal-title":"Diabetes Care"},{"key":"2025080104321667600_ciae542-B28","doi-asserted-by":"crossref","first-page":"e0211483","DOI":"10.1371\/journal.pone.0211483","article-title":"Glycated haemoglobin threshold for dysglycaemia screening, and application to metabolic syndrome diagnosis in HIV-infected Africans","volume":"14","author":"Nguyen","year":"2019","journal-title":"PLoS One"},{"key":"2025080104321667600_ciae542-B29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/25787489.2020.1766864","article-title":"Correlation between plasma glucose and hemoglobin A1c in HIV-infected individuals receiving zidovudine and non-zidovudine containing antiretroviral therapy regimens","volume":"21","author":"Saetang","year":"2020","journal-title":"HIV Res Clin Pract"},{"key":"2025080104321667600_ciae542-B30","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/09564624231162163","article-title":"Hba1c screening for diabetes mellitus and to evaluate diabetic control in people of African ancestry with HIV in South London","volume":"34","author":"Cechin","year":"2023","journal-title":"Int J STD AIDS"},{"key":"2025080104321667600_ciae542-B31","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","article-title":"Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis","volume":"3","author":"Kanters","year":"2016","journal-title":"Lancet HIV"},{"key":"2025080104321667600_ciae542-B32","doi-asserted-by":"crossref","first-page":"e105653","DOI":"10.1371\/journal.pone.0105653","article-title":"48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis","volume":"9","author":"Patel","year":"2014","journal-title":"PLoS One"},{"key":"2025080104321667600_ciae542-B33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","journal-title":"Hepatology"},{"author":"American Association for the Study of Liver Disease\u2014Infectious Diseases Society of America 2024","key":"2025080104321667600_ciae542-B34"},{"key":"2025080104321667600_ciae542-B35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"2025080104321667600_ciae542-B36","first-page":"1746","article-title":"Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy","volume":"173","author":"Hyle","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2025080104321667600_ciae542-B37","doi-asserted-by":"crossref","first-page":"e999","DOI":"10.1097\/PTS.0000000000001002","article-title":"Patient safety issues from information overload in electronic medical records","volume":"18","author":"Nijor","year":"2022","journal-title":"J Patient Saf"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae542\/61017431\/ciae542.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/1\/113\/61017431\/ciae542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/1\/113\/61017431\/ciae542.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T08:33:00Z","timestamp":1754037180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/1\/113\/7919927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,10]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae542","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published-other":{"date-parts":[[2025,7,15]]},"published":{"date-parts":[[2024,12,10]]}}}